Small logo Subscribe to leading news on impact investing. Learn More
The Brief Originals Dealflow Signals The Impact Alpha Impact Voices Podcasts Agents of Impact Open
What's Next Capital on the Frontier Measure Better Investing in Racial Equity Beyond Trade-offs Impact en las Americas New Revivalists
Local and Inclusive Climate Finance Catalytic Capital Frontier Finance Best Practices Geographies
Slack Agent of Impact Calls Events Contribute
The Archive ImpactSpace The Accelerator Selection Tool Network Map
About Us FAQ Calendar Pricing and Payment Policy Privacy Policy Terms of Service Agreement Contact Us
Locavesting Entrepreneurship Gender Smart Return on Inclusion Good Jobs Creative economy Opportunity Zones Investing in place Housing New Schooled Well Being People on the Move Faith and investing Inclusive Fintech
Clean Energy Farmer Finance Soil Wealth Conservation Finance Financing Fish
Innovative Finance
Personal Finance Impact Management
Africa Asia Europe Latin America Middle East Oceania/Australia China Canada India United Kingdom United States
Subscribe
Features
Series
Themes
Community
Data
Subscribe Log In
More

Two Gates Foundation alumni raise $200 million for biotech and health venture fund



Two Gates Foundation alumni have raised $200 million for a biotech and health venture fund.

Biomatics Capital, based in Seattle, will invest $5 million to $10 million in companies focused on the cutting edge of genomics and data-driven health care.

The principals are Boris Nikolic, the former chief science adviser to Bill Gates, and Julie Sunderland, who ran the foundation’s $1.5 billion mandate for program-related investments.

Under Sunderland’s direction, the Gates Foundation invested $167 million in 14 biotech companies looking for vaccines and drugs for diseases such as malaria, HIV, and typhoid (see David Bank’s Q&A with Sunderland, “Leveraging the Balance Sheet”).

Nikolic helped Bill himself invest in Editas Medicine Inc., which is developing the powerful — and controversial — DNA-editing technology known as CRISPR, and serves on Editas’ board of directors.

Biomatics has invested in eight companies, including AiCure in New York, which uses smartphones to track when patients take their medications.

This post originally appeared in ImpactAlpha’s daily newsletter. Get The Brief.

You might also like...